← HALOZYME THERAPEUTICS, INC. HALO
Market Price
$98.66
Market Cap
$11.94B
P/E Ratio
38.54
Revenue (FY 2025)
↑37.6% YoY
$1.40B
3-Yr CAGR: 28.4%
Net Income
↓-28.6% YoY
$316.89M
Net Margin: 22.7%
Free Cash Flow
↑37.6% YoY
$644.59M
FCF Yield: 5.40%
EPS (Diluted)
↓-25.4% YoY
$2.56
Basic: $2.64
Return on Equity
Efficiency
649.2%
ROA: 490.2%
⚡ Elevated ROE due to low book equity from buybacks
📊 Multi-Year Historical Performance & Trends
Financial Performance History
Revenue, Net Income & Free Cash Flow
Margins Trend (%)
Gross, Operating & Net Margins
Balance Sheet Strength
Cash, Debt & Equity
Cash Flow Generation
Operating Cash Flow vs CapEx vs FCF
📈 Year-over-Year (YoY) Growth History (HALO)
All monetary values in millions ($M)| Fiscal Year | Revenue | Revenue YoY | Gross Profit | Net Income | Net Inc YoY | Diluted EPS | EPS YoY | Op. Cash Flow | Free Cash Flow | FCF YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2016 | $146.7M | — | $113.5M | $-103.0M | — | $-0.81 | — | $-50.4M | $-53.5M | — |
| FY 2017 | $316.6M | +115.8% | $285.5M | $63.0M | +161.1% | $0.45 | +155.6% | $134.1M | $132.7M | +348.0% |
| FY 2018 | $151.9M | -52.0% | $133.8M | $-80.3M | -227.6% | $-0.56 | -224.4% | $-49.5M | $-54.2M | -140.8% |
| FY 2019 | $196.0M | +29.1% | $150.4M | $-72.2M | +10.1% | $-0.50 | +10.7% | $-85.4M | $-89.5M | -65.2% |
| FY 2020 | $267.6M | +36.5% | $224.2M | $129.1M | +278.7% | $0.91 | +282.0% | $55.5M | $53.0M | +159.2% |
| FY 2021 | $443.3M | +65.7% | $361.9M | $402.7M | +212.0% | $2.74 | +201.1% | $299.4M | $298.0M | +462.8% |
| FY 2022 | $660.1M | +48.9% | $520.8M | $202.1M | -49.8% | $1.44 | -47.4% | $240.1M | $235.3M | -21.0% |
| FY 2023 | $829.3M | +25.6% | $636.9M | $281.6M | +39.3% | $2.10 | +45.8% | $388.6M | $373.3M | +58.6% |
| FY 2024 | $1,015.3M | +22.4% | $855.9M | $444.1M | +57.7% | $3.43 | +63.3% | $479.1M | $468.4M | +25.5% |
| FY 2025 | $1,396.6M | +37.6% | $1,167.8M | $316.9M | -28.6% | $2.56 | -25.4% | $651.6M | $644.6M | +37.6% |
Valuation
Market Price
$98.66
Market Cap
$11.94B
Enterprise Value
$13.95B
P/E Ratio
38.54
P/B Ratio
239.72
FCF Yield
5.40%
Dividend Yield
N/A
Shares Outstanding
Profitability & Margins
Gross Margin
83.62%
Operating Margin
33.58%
Net Margin
22.69%
Return on Equity (ROE)
649.18%
Return on Assets (ROA)
490.24%
Asset Turnover
21.61x
Revenue 3-Yr CAGR
28.38%
Financial Health & Liquidity
Current Ratio
0.41
Cash Ratio
0.86
Debt / Equity
43.894
Debt / Assets
33.148
Cash & Equivalents
$133.82M
Total Debt
$2.14B
Book Value / Share
$0.41
Cash Flow Efficiency
Operating Cash Flow
$651.56M
Capital Expenditures (CapEx)
$6.97M
Free Cash Flow
$644.59M
OCF / Revenue
46.65%
FCF / Revenue
46.15%
FCF 3-Yr CAGR
39.92%
Per Share Metrics
EPS (Diluted)
$2.56
EPS (Basic)
$2.64
Dividends / Share
N/A
Book Value / Share
$0.41
EPS YoY Growth
-25.36%
Balance Sheet (FY 2025)
Total Assets
$64.64M
Total Liabilities
$156.19M
Stockholders' Equity
$48.81M
Current Assets
$64.64M
Current Liabilities
$156.19M